Phase 2 × Myeloproliferative Disorders × Lymphoid × Clear all
NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Thomas Jefferson University

Phase 2 Completed
40 enrolled 15 charts
NCT06059391 2026-03-10

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

City of Hope Medical Center

Phase 2 Recruiting
216 enrolled
NCT06001385 2026-02-05

OPTIMIZE

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
313 enrolled
NCT06013423 2026-01-22

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Fred Hutchinson Cancer Center

Phase 2 Recruiting
54 enrolled
NCT04191187 2025-12-11

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
34 enrolled 14 charts
NCT04060277 2025-11-14

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

City of Hope Medical Center

Phase 2 Active not recruiting
7 enrolled 12 charts
NCT03779854 2025-10-15

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Recruiting
68 enrolled
NCT02506933 2025-08-22

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 2 Active not recruiting
102 enrolled 10 charts
NCT02722668 2025-07-04

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
15 enrolled 15 charts
NCT03333486 2025-07-04

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Roswell Park Cancer Institute

Phase 2 Terminated
31 enrolled 18 charts
NCT05805605 2025-07-01

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
56 enrolled
NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
NCT03314974 2025-06-24

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
300 enrolled
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT04996875 2025-05-30

APEX

Cogent Biosciences, Inc.

Phase 2 Recruiting
140 enrolled
NCT02988466 2025-05-28

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
78 enrolled 16 charts
NCT02566304 2025-04-24

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
35 enrolled 14 charts
NCT02396134 2025-03-03

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

City of Hope Medical Center

Phase 2 Completed
61 enrolled 10 charts
NCT03128359 2024-01-09

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

City of Hope Medical Center

Phase 2 Completed
38 enrolled 11 charts
NCT02639559 2023-11-07

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Washington University School of Medicine

Phase 2 Completed
50 enrolled 23 charts
NCT00611351 2023-10-23

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

University of Nebraska

Phase 2 Completed
5 enrolled 10 charts
NCT02556931 2022-11-03

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
117 enrolled 27 charts
NCT03602898 2021-06-30

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Withdrawn
NCT00489203 2021-02-03

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
140 enrolled
NCT00005797 2020-12-10

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
125 enrolled
NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

M.D. Anderson Cancer Center

Phase 2 Completed
176 enrolled 18 charts
NCT00053989 2020-02-10

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Roswell Park Cancer Institute

Phase 2 Completed
41 enrolled 13 charts
NCT00040846 2020-01-29

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
60 enrolled 10 charts
NCT00723099 2019-12-27

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
73 enrolled 23 charts
NCT00105001 2019-10-30

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
210 enrolled 15 charts
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT00044954 2019-09-17

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Texas Southwestern Medical Center

Phase 2 Completed
NCT01159067 2019-06-18

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

City of Hope Medical Center

Phase 2 Terminated
1 enrolled 4 charts